TIDMCREO

RNS Number : 8013A

Creo Medical Group PLC

04 June 2021

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Posting of Annual Reports & Accounts

Notice of Annual General Meeting

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, confirms that the Annual Report and Accounts for the year ended 31 December 2020 (the "2020 Annual Report & Accounts") and the Notice of the Company's Annual General Meeting ("AGM") have now been published on the Company's website at https://creomedical.com/investors/reports-and-presentations/ with hard copies being posted to those shareholders who have not elected to receive electronic communication from the Company.

Notice of AGM

The AGM will be held on Wednesday, 30 June 2021 at 10:00 am at the offices of Osborne Clarke, 2 Temple Back East, Temple Quay, Bristol BS1 6EG.

The Directors recognise the vast improvement to the UK's COVID situation, however in light of the Company's ongoing desire to protect the health and safety of its shareholders and employees, the Directors recommend shareholders to not attend the AGM in person but vote via proxy.

Shareholders are recommended to appoint the chair of the meeting as their proxy rather than a named person, as any such named person may not be permitted to attend the AGM in the event of unforeseen circumstances (e.g. if they are required to self isolate).

If you wish to attend the meeting in person you are asked to confirm your attendance by emailing creo@walbrookpr.com no later than 5pm on 25 June 2021. All attendees will be required to follow all relevant COVID-19 safety procedures whilst on site.

Should the number of shareholders who notify us of their intention to attend the meeting in person result in our needing to make alternative arrangements to ensure that we can accommodate everyone safely, then this will be notified to shareholders via the regulatory news service.

The Annual General Meeting will comprise only the formal votes on each resolution as set out in Notice, without any business update or Q&As.

Voting will be conducted on each resolution by way of a poll. All shareholders are invited to submit questions on the resolutions to be proposed at the AGM electronically before the AGM and such questions, limited to matters relating to the business of the AGM itself, should be sent to creo@walbrookpr.com by no later than 5pm on 25th June 2021 and these will be responded to on an individual basis. Any questions raised, together with answers to them, will be published on the Company's website at https://creomedical.com/investors/reports-and-presentations by 5.00 pm on 28 June 2021.

 
 Creo Medical Group plc                                           investors.creomedical.com 
 Richard Rees (CFO)                                                     +44 (0)1291 606 005 
 
 Cenkos Securities                                                      +44 (0)20 7397 8900 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: +44 ( 0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus / Lianne Cawthorne                     Mob: +44 (0)7980 541 893 / +44 (0)7515 
                                                                                    909 238

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that delivers bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by its full spectrum Kamaptive Technology to market, enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. An overview of the Creo Medical device technology portfolio can be seen here:

https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf

For more information about Creo Medical please see our website, www.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUOOBRAWUNRAR

(END) Dow Jones Newswires

June 04, 2021 02:01 ET (06:01 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Creo Medical Charts.